Stockpolly
Search
WHWK · NASDAQ · Biotechnology

Whitehawk Therapeutics (WHWK)

Develops in-licensed antibody-drug conjugates for cancer treatment.

$4.64
Pre-market−0.08 (−1.59%)
At close$4.72(+1.84%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue665677700000
Cost of revenue131414141115100000
Gross profit−7−7−9−8−4−8600000
11101181011225520252418
Research & development12131413101494914191713
Selling, general & administrative11101187111365665
Other expenses−12−13−14−13−7−14000000
Operating income−18−18−20−16−13−19−15−55−20−25−24−18
2111118822211
Interest income221111122211
Interest expense000000000000
Other non-operating income0−2−1−1−3−1−88−2−2−2−10
Income before tax−16−16−18−15−13−1873−53−18−23−22−17
Net income from continuing operations−16−16−18−15−13−1873−53−18−23−22−17
Net income−16−16−18−15−13−1873−53−18−23−22−17
EPS, basic−$0.60−$0.60−$0.68−$0.54−$0.46−$0.67$1.84−$0.76−$0.26−$0.34−$0.32−$0.20
EPS, diluted−$0.60−$0.60−$0.68−$0.54−$0.46−$0.67$1.83−$0.76−$0.26−$0.34−$0.32−$0.20
Weighted average shares, basic272727272727276968696983
Weighted average shares, diluted272727272727276969696983
EBITDA−18−16−18−14−11−1873−53−18−23−22−18
Depreciation & amortization000000000000
EBIT−18−16−18−15−11−1873−53−18−23−22−18